Molecular and cellular mechanisms of heterotopic ossification

Histology and Histopathology

Volumn 29, Issue 10, 2014, Pages 1281-1285

  Ramirez, Diana M ^a,b   Ramirez, Melissa R ^a,b   Reginato, Anthony M ^a   Medici, Damian ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Bone; Fibrodysplasia ossificans progressiva; FOP; Heterotopic ossification; HO

Indexed keywords

ANIMAL; GENETICS; HUMAN; OSSIFICATION, HETEROTOPIC; PATHOLOGY;

ANIMALS; HUMANS; OSSIFICATION, HETEROTOPIC;

EID: 84907250732     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Bagarova J., Vonner A.J., Armstrong K.A., Borgermann J., Lai C.S., Deng D.Y., Beppu H., Alfano I., Filippakopoulos P., Morrell N.W., Bullock A.N., Knaus P., Mishina Y. and Yu P.B. (2013). Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol. Cell. Biol. 33, 2413-2424.
2. Bocciardi R., Bordo D., Di Duca M., Di Rocco M. and Ravazzolo, R. (2009). Mutational Analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur. J. Hum. Genet. 17, 311-318.
3. Chakkalakal S.A., Zhang D., Culbert A.L., Convente M.R., Caron R.J., Wright A.C., Maidment A.D., Kaplan F.S. and Shore E.M. (2012). An ACVR1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 27, 1746-1756
4. Connor J.M. and Evans D.A. (1982). Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J. Bone Joint Surg. Br. 64, 76-83.
5. Furuya H., Ikezoe K., Wang L., Ohyagi Y., Motomura K., Fujii N., Kira J. and Fukumaki Y. (2008). A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am. J. Med. Genet. A 146A, 459-463.
6. Gannon F.H., Kaplan F.S., Olmsted, E., Finkel, G.C., Zasloff, M.A. and Shore E. (1997). Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum. Pathol. 28, 339-343.
7. Gregson C.L., Holingworth P., Williams M., Petrie K.A., Bullock A.N., Brown M.A., Tobias J.H. and Triffitt, J.T. (2011). A novel ACVR1 mutation in the glycine/serine rich domain found in the most benign case of fibrodysplasia ossificans progressiva variant reported to date. Bone 48, 654-658.
8. Grenier G., Leblanc E., Faucheux N., Lauzier D., Kloen P. and Hamdy R.C. (2013). BMP-9 expression in human traumatic heterotopic ossification: a case report. Skeletal Muscle 3, 29.
9. Kan L., Liu Y., McGuire T.L., Berger D.M., Awatramani R.B., Dymecki S.M. and Kessler J.A. (2009). Dysregulation of local stem/progenitor cells as a common cellular mechanism of heterotopic ossification. Stem Cells 27, 150-156.
10. Kan L., Lounev V.Y., Pignolo R.J., Duan L., Liu Y., Stock S.R., McGuire T.L., Lu B., Gerard N.P., Shore E.M., Kaplan F.S. and Kessler J.A. (2011). Substance P signaling mediates BMP-dependent heterotopic ossification. J. Cell. Biochem. 112, 2759-2772.
11. Kan L., Peng C.Y., McGuire T.L. and Kessler J.A. (2013). Glast-expressing progenitor cells contribute to heterotopic ossification. Bone 53, 194-203.
12. Kaplan F.S., Xu M., Seemann P., Connor J.M., Glaser D.L., Carroll L., Delai P., Fastnaucht-Urban E., Forman S.J., Gillessen-Kaesbach G., Hoover-Fong J., Koster B., Pauli, R.M., Reardon W., Zaidi S.A., Zasloff M., Morhart R., Mundlos S., Groppe J. and Shore E.M. (2009). Classic and atypical fibrodysplasia ossificans progressive (FOP) phenotypes are caused by mutations in the bone morphogenic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30, 379-390.
13. Kaplan F.S., Chakkalakal S.A. and Shore E.M. (2012). Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis. Model. Mech. 5, 756-762.
14. Kitterman J.A., Kantanie S., Rocke D.M. and Kaplan F.S. (2005). Latrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116, e654-e661.
15. Kussmaul W.G., Esmail A.N., Sagar Y., Ross J., Gregory S. and Kaplan F.S. (1998). Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 346, 104-109.
16. Leblanc E., Trensz F., Haroun S., Droulin G., Bergeron E., Penton C.M., Montanaro F., Roux S., Faucheux N. and Grenier G. (2011). BMP-9-induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment. J. Bone Miner. Res. 26, 1166-1177.
17. Lounev V.Y., Ramachandran R., Wosczyna M.N., Yamamoto M., Maidment A.D., Shore E.M., Glaser D.L., Goldhamer D.J. and Kaplan F.S. (2009). Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Joint Surg. Am. 91, 652-663.
18. Medici D., Shore E.M., Lounev V.Y., Kaplan F.S., Kalluri R. and Olsen B.R. (2010). Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406.
19. Mu X., Usas A., Tang Y., Lu A., Wang B., Weiss K. and Huard J. (2013). RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice. FASEB J. 27, 3619-3631.
20. Nakahara Y., Katagiri T., Ogata N. and Haga N. (2014). ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report. Am. J. Med. Genet. A. 164A, 220-224.
21. Petrie K.A., Lee W.H., Bullock A.N., Pointon J.J., Smith R., Russell R.G., Brown M.A., Wordsworth B.P. and Triffitt J.T. (2009). Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One 4, e5005.
22. Pignolo R.J., Shore E.M. and Kaplan F.S. (2011). Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J. Rare Dis. 6, 80.
23. Salisbury E., Rodenberg E., Sonnet C., Hipp J., Gannon F.H., Vadakkan T.J., Dickinson M.E., Olmsted-Davis E.A. and Davis A.R. (2011). Sensory nerve induced inflammation contributes to heterotopic ossification. J. Cell. Biochem. 112, 2748-2758.
24. Shen Q., Little S.C., Xu M., Haupt J., Ast C., Katagiri T., Mundlos S., Seeman P., Kaplan F.S., Mullins M.C. and Shore E.M. (2009). The fibrodysplasia ossificans progressive R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J. Clin. Invest. 119, 3462-3472.
25. Shimono K., Tung W., Macolino C., Chi A.H., Didizian J.H., Mundy C., Chandraratna R.A., Mishina Y., Enomoto-Iwamoto M., Pacifici M. and Iwamoto M. (2011). Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat. Med. 17, 454-460.
26. Shore E.M. and Kaplan F.S. (2010). Inherited human diseases of heterotopic ossification. Nat. Rev. Rhuematol. 6, 518-527.
27. Shore E.M., Xu M., Feldman G.J., Fenstermacher D.A., Cho T.J., Choi I.H., Connor J.M., Delai P., Glaser D.L., LeMerrer M., Morhart R., Rogers J.G., Smith R., Triffitt J.T., Urtizberea J.A., Zasloff M., Brown M.A. and Kaplan F.S. (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38, 525-527.
28. Whyte, M.P., Wenkert D., Demerzis J.L., DiCarlo E.F., Westenberg E. and Mumm S. (2012). Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1. J. Bone Miner. Res. 27, 729-737.
29. Wosczyna M.N., Biswas A.A., Cogswell C.A. and Goldhamer D.J. (2012). Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J. Bone Miner. Res. 27, 1004-1017.
30. Yao Y., Jumabay M., Ly A., Radparvar M., Cubberly M.R. and Bostrom K.I. (2013). A role for the endothelium in vascular calcification. Circ. Res. 113, 495-504.
31. Yu P.B., Deng D.Y., Lai C.S., Hong C.C., Cuny G.D., Bouxsein M.L., Hong D.W., McManus P.M., Katagiri T., Sachidanandan C., Kamiya N., Fukuda T., Mishina Y., Peterson R.T. and Bloch K.D. (2008). BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 14, 1363-1369.